Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Joseph T. Coyle, M.D.

TitleEben S. Draper Professor of Psychiatry
InstitutionMcLean Hospital
DepartmentPsychiatry
AddressMclean Hospital
Mailman Research Center
115 Mill St
Belmont MA 02478
Phone617/855-2101
Fax617/855-2705

 Biography 
 awards and honors
1968 - Henry Strong Denison Research Scholarship
1969 - Alpha Omega Alpha Student Research Award
1978 - A.E.Bennett Award in Basic Science
1979 - John Jacob Abel Award
1979 - Sato International Memorial Award
1982 - Daniel Efron Award
1985 - Foundations' Fund Prize for Research in Psychiatry
1986 - Alpha Omega Alpha Honor Society
1990 - Institute of Medicine of the National Academy of Sciences
1990 - Nancy and Daniel Weisman Award for Research on Mental Retardation
1991 - Edward A. Strecker Award
1991 - Gold Medal Award
1991 - 1992President
1992 - William R. McAlpin, Jr. Research Achievement Award
1994 - Fellow
1997 - Award for Neuropsychiatric Research
1997 - Exemplary Psychiatrist Award
2001 - 2002 President
2001 - 2001 Highly Cited Researchers Award
2001 - 2004Council
2001 - Special Achievement Award
2004 - Lieber Prize for Schizophrenia Research
2006 - Fellow
2007 - 2007 Sanctae Crucis Award
2007 - 2008 Julius Axelrod Award

 Overview 
 overview
Joseph T. Coyle, M.D. holds the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard Medical School. From 1991 to 2001, he served as Chairman of the Consolidated Department of Psychiatry at Harvard Medical School, which included the nine hospital programs of psychiatry affiliated with the Medical School. After graduating from Holy Cross College, he received his medical degree (M.D.) from Johns Hopkins School of Medicine in 1969. Following an internship in Pediatrics, he spent three years at the National Institutes of Health as a research fellow in the laboratory of Nobel laureate Julius Axelrod, Ph.D. He returned to Hopkins in 1973 to complete his Psychiatric residency, in which he is board certified, and joined the faculty in 1975. In 1980, he was promoted to Professor of Neuroscience, Pharmacology and Psychiatry; and in 1982 he assumed the Directorship of the Division of Child and Adolescent Psychiatry, being named the Distinguished Service Professor in 1985.

Dr. Coyle's research interests include developmental neurobiology, mechanisms of neuronal vulnerability and psychopharmacology. In particular, he has carried out research on the role of glutamatergic neurons in the pathophysiology of neuropsychiatric disorders for 30 years. He has a long commitment to training. In the mid-1980s, he was the PI of a NIMH Training Grant that had a core curriculum, which introduced PhD fellows to psychiatric illnesses with patient demonstrations. While President of the Society of Neuroscience, he worked with NIMH to develop a minority Training Grant. For the last 10 years, he has served as co-PI on this grant, which was the foundation for minority mentoring and net-working for the Society. He has published over 500 scientific articles and has edited seven books. His research has been cited over 35,000 times, and his H-factor is 93. He has received continuous NIH funding for his research for 30 years and is the Director of an NIMH Conte Center on the Neurobiology of Schizophrenia (2001-11).

Dr. Coyle is a member of the Institute of Medicine of the National Academy of Sciences (1990), a fellow of the American Academy of Arts and Sciences (1993), a Distinguished Fellow of the American Psychiatric Association, a fellow of the American College of Psychiatry and fellow of the American Association for the Advancement of Science. He served on the National Advisory Mental Health Council for the National Institute of Mental Health (1990-94). He is Past-President of the American College of Neuropsychopharmacology (2001) and Past-President (1991) of the Society for Neuroscience, an organization with more than 35,000 members. He sits on over 20 journal editorial boards including JAMA and is the Editor-in-Chief of the Archives of General Psychiatry, the most highly cited journal in the field (citation impact:15.98).


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Santini MA, Balu DT, Puhl MD, Hill-Smith TE, Berg AR, Lucki I, Mikkelsen JD, Coyle JT. D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT2A receptor agonist DOI. Behav Brain Res. 2014 Feb 1; 259:242-6.
    View in: PubMed
  2. Coyle JT, Ongur D. Relapse in alcohol use disorder-reply. JAMA Psychiatry. 2013 Nov 1; 70(11):1248.
    View in: PubMed
  3. Coyle JT. Brain structural alterations induced by fetal exposure to cocaine persist into adolescence and affect behavior. JAMA Psychiatry. 2013 Oct 1; 70(10):1113-4.
    View in: PubMed
  4. Coyle JT. Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry. 2013 Jul 1; 70(7):664-5.
    View in: PubMed
  5. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S, Bolshakov VY, Coyle JT. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A. 2013 Jun 25; 110(26):E2400-9.
    View in: PubMed
  6. Konopaske GT, Bolo NR, Basu AC, Renshaw PF, Coyle JT. Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. Psychopharmacology (Berl). 2013 Nov; 230(1):57-67.
    View in: PubMed
  7. Li Y, Sacchi S, Pollegioni L, Basu AC, Coyle JT, Bolshakov VY. Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nat Commun. 2013 Apr 23; 4:1760.
    View in: PubMed
  8. Coyle JT. Much more than a name change. JAMA Psychiatry. 2013 Jan 1; 70(1):8.
    View in: PubMed
  9. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012 Sep; 38(5):920-6.
    View in: PubMed
  10. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA network journals: new names for the archives journals. Arch Intern Med. 2012 Jul 23; 172(14):1056.
    View in: PubMed
  11. Benneyworth MA, Coyle JT. Altered acquisition and extinction of amphetamine-paired context conditioning in genetic mouse models of altered NMDA receptor function. Neuropsychopharmacology. 2012 Oct; 37(11):2496-504.
    View in: PubMed
  12. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network journals: new names for the archives journals. Arch Facial Plast Surg. 2012 Jul-Aug; 14(4):236.
    View in: PubMed
  13. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: new names for the archives journals. Arch Pediatr Adolesc Med. 2012 Jul 1; 166(7):662.
    View in: PubMed
  14. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Neurol. 2012 Jul 1; 69(7):817.
    View in: PubMed
  15. Coyle JT. Changing to JAMA Psychiatry. Arch Gen Psychiatry. 2012 Jul 1; 69(7):661.
    View in: PubMed
  16. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Neurol. 2012 Jul 1; 69(7):817.
    View in: PubMed
  17. Coyle JT. Changing to JAMA Psychiatry. Arch Gen Psychiatry. 2012 Jul 1; 69(7):661.
    View in: PubMed
  18. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Otolaryngol Head Neck Surg. 2012 Jul 1; 138(7):620.
    View in: PubMed
  19. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Ophthalmol. 2012 Jul 1; 130(7):914.
    View in: PubMed
  20. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Gen Psychiatry. 2012 Jul 1; 69(7):660.
    View in: PubMed
  21. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network journals: new names for the archives journals. Arch Surg. 2012 Jul; 147(7):587.
    View in: PubMed
  22. Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: new names for the archives journals. Arch Dermatol. 2012 Jul; 148(7):788.
    View in: PubMed
  23. Schaevitz LR, Picker JD, Rana J, Kolodny NH, Shane B, Berger-Sweeney JE, Coyle JT. Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders. Dev Neurobiol. 2012 Jun; 72(6):891-905.
    View in: PubMed
  24. Coyle JT. Changes in JAMA and the Archives of General Psychiatry: what they mean for readers and authors. Arch Gen Psychiatry. 2012 May; 69(5):447-8.
    View in: PubMed
  25. Balu DT, Coyle JT. Neuronal D-serine regulates dendritic architecture in the somatosensory cortex. Neurosci Lett. 2012 May 31; 517(2):77-81.
    View in: PubMed
  26. Benneyworth MA, Li Y, Basu AC, Bolshakov VY, Coyle JT. Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons. Cell Mol Neurobiol. 2012 May; 32(4):613-24.
    View in: PubMed
  27. Chen Y, Norton DJ, McBain R, Gold J, Frazier JA, Coyle JT. Enhanced local processing of dynamic visual information in autism: evidence from speed discrimination. Neuropsychologia. 2012 Apr; 50(5):733-9.
    View in: PubMed
  28. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol. 2012; (213):267-95.
    View in: PubMed
  29. Bergeron R, Coyle JT. NAAG, NMDA receptor and psychosis. Curr Med Chem. 2012; 19(9):1360-4.
    View in: PubMed
  30. Sullivan SJ, Esguerra M, Wickham RJ, Romero GE, Coyle JT, Miller RF. Serine racemase deletion abolishes light-evoked NMDA receptor currents in retinal ganglion cells. J Physiol. 2011 Dec 15; 589(Pt 24):5997-6006.
    View in: PubMed
  31. Balu DT, Basu AC, Corradi JP, Cacace AM, Coyle JT. The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol Dis. 2012 Feb; 45(2):671-82.
    View in: PubMed
  32. Balu DT, Coyle JT. Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Res. 2011 May 25; 1392:1-7.
    View in: PubMed
  33. Coyle JT. Online first. Arch Gen Psychiatry. 2011 Apr 4; 68(4):339.
    View in: PubMed
  34. Benneyworth MA, Roseman AS, Basu AC, Coyle JT. Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neurosci Lett. 2011 Jan 25; 488(3):267-71.
    View in: PubMed
  35. DeVito LM, Balu DT, Kanter BR, Lykken C, Basu AC, Coyle JT, Eichenbaum H. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav. 2011 Mar; 10(2):210-22.
    View in: PubMed
  36. Balu DT, Coyle JT. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev. 2011 Jan; 35(3):848-70.
    View in: PubMed
  37. Benneyworth MA, Basu AC, Coyle JT. Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology (Berl). 2011 Jan; 213(1):143-53.
    View in: PubMed
  38. Mustafa AK, Ahmad AS, Zeynalov E, Gazi SK, Sikka G, Ehmsen JT, Barrow RK, Coyle JT, Snyder SH, Doré S. Serine racemase deletion protects against cerebral ischemia and excitotoxicity. J Neurosci. 2010 Jan 27; 30(4):1413-6.
    View in: PubMed
  39. Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010; 12(3):359-82.
    View in: PubMed
  40. Reed BT, Sullivan SJ, Tsai G, Coyle JT, Esguerra M, Miller RF. The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. Eur J Neurosci. 2009 Dec; 30(12):2308-17.
    View in: PubMed
  41. Han L, Picker JD, Schaevitz LR, Tsai G, Feng J, Jiang Z, Chu HC, Basu AC, Berger-Sweeney J, Coyle JT. Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse. 2009 Aug; 63(8):625-35.
    View in: PubMed
  42. Ghose S, Chin R, Gallegos A, Roberts R, Coyle J, Tamminga C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr Res. 2009 Jun; 111(1-3):131-7.
    View in: PubMed
  43. Coyle JT. MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proc Natl Acad Sci U S A. 2009 Mar 3; 106(9):2975-6.
    View in: PubMed
  44. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, Jiang ZI, Benneyworth MA, Froimowitz MP, Lange N, Snyder SH, Bergeron R, Coyle JT. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry. 2009 Jul; 14(7):719-27.
    View in: PubMed
  45. Coyle JT. Erratum: "Prevalence, heritability, and prospective risk factors for anorexia nervosa" (2006;63[3]:305-312). Arch Gen Psychiatry. 2008 Sep; 65(9):994.
    View in: PubMed
  46. Regenberg A, Mathews DJ, Blass DM, Bok H, Coyle JT, Duggan P, Faden R, Finkel J, Gearhart JD, Hillis A, Hoke A, Johnson R, Johnston M, Kahn J, Kerr D, King P, Kurtzberg J, Liao SM, McDonald JW, McKhann G, Nelson KB, Rao M, Siegel AW, Smith K, Solter D, Song H, Sugarman J, Vescovi A, Young W, Greely HT, Traystman RJ. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab. 2009 Jan; 29(1):1-9.
    View in: PubMed
  47. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008 May; 31(5):234-42.
    View in: PubMed
  48. Eaton DL, Daroff RB, Autrup H, Bridges J, Buffler P, Costa LG, Coyle J, McKhann G, Mobley WC, Nadel L, Neubert D, Schulte-Hermann R, Spencer PS. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit Rev Toxicol. 2008; 38 Suppl 2:1-125.
    View in: PubMed
  49. Lawson-Yuen A, Liu D, Han L, Jiang ZI, Tsai GE, Basu AC, Picker J, Feng J, Coyle JT. Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. Brain Res. 2007 Nov 14; 1180:1-6.
    View in: PubMed
  50. Han L, Wong DL, Tsai G, Jiang Z, Coyle JT. Promoter analysis of human glutamate carboxypeptidase II. Brain Res. 2007 Sep 19; 1170:1-12.
    View in: PubMed
  51. Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis. 2007 Jul; 11(4):491-507.
    View in: PubMed
  52. Coyle JT. What can a clock mutation in mice tell us about bipolar disorder? Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6097-8.
    View in: PubMed
  53. Bergeron R, Imamura Y, Frangioni JV, Greene RW, Coyle JT. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J Neurochem. 2007 Jan; 100(2):346-57.
    View in: PubMed
  54. Coyle JT. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec; 10(3-4):221-33.
    View in: PubMed
  55. Siekmeier PJ, Hasselmo ME, Howard MW, Coyle J. Modeling of context-dependent retrieval in hippocampal region CA1: implications for cognitive function in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):177-90.
    View in: PubMed
  56. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron. 2006 Oct 5; 52(1):139-53.
    View in: PubMed
  57. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 Jul-Aug; 26(4-6):365-84.
    View in: PubMed
  58. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2007 Jan 15; 61(2):162-6.
    View in: PubMed
  59. Coyle JT. A brief overview of N-acetylaspartate and N-acetylaspartylglutamate. Adv Exp Med Biol. 2006; 576:1-6; discussion 361-3.
    View in: PubMed
  60. Coyle JT. Glial metabolites of tryptophan and excitotoxicity: coming unglued. Exp Neurol. 2006 Jan; 197(1):4-7.
    View in: PubMed
  61. Picker JD, Coyle JT. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harv Rev Psychiatry. 2005 Jul-Aug; 13(4):197-205.
    View in: PubMed
  62. Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005 Jan 30; 138(1):23-31.
    View in: PubMed
  63. Martina M, B-Turcotte ME, Halman S, Tsai G, Tiberi M, Coyle JT, Bergeron R. Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. J Physiol. 2005 Mar 15; 563(Pt 3):777-93.
    View in: PubMed
  64. Bergeron R, Coyle JT, Tsai G, Greene RW. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology. 2005 Jan; 30(1):7-16.
    View in: PubMed
  65. Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol. 2004 Oct 15; 68(8):1507-14.
    View in: PubMed
  66. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004 Sep; 161(9):1705-8.
    View in: PubMed
  67. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A. 2004 Jun 1; 101(22):8485-90.
    View in: PubMed
  68. Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol. 2004; 59:491-515.
    View in: PubMed
  69. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, Kleinman JE. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology. 2004 Jan; 29(1):117-25.
    View in: PubMed
  70. Javitt DC, Coyle JT. Decoding schizophrenia. Sci Am. 2004 Jan; 290(1):48-55.
    View in: PubMed
  71. Tsai G, Dunham KS, Drager U, Grier A, Anderson C, Collura J, Coyle JT. Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse. 2003 Dec 15; 50(4):285-92.
    View in: PubMed
  72. Coyle JT, Pine DS, Charney DS, Lewis L, Nemeroff CB, Carlson GA, Joshi PT, Reiss D, Todd RD, Hellander M. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2003 Dec; 42(12):1494-503.
    View in: PubMed
  73. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):32-8.
    View in: PubMed
  74. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003 Nov; 1003:318-27.
    View in: PubMed
  75. Coyle JT. Use it or lose it--do effortful mental activities protect against dementia? N Engl J Med. 2003 Jun 19; 348(25):2489-90.
    View in: PubMed
  76. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 2003 Apr 24; 38(2):157-60.
    View in: PubMed
  77. Flores C, Coyle JT. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology. 2003 Jul; 28(7):1227-34.
    View in: PubMed
  78. Coyle JT. A continuing commitment to excellence. Arch Gen Psychiatry. 2002 Nov; 59(11):977.
    View in: PubMed
  79. Coyle JT, Manji HK. Getting balance: drugs for bipolar disorder share target. Nat Med. 2002 Jun; 8(6):557-8.
    View in: PubMed
  80. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002 Apr; 1(2):183-9.
    View in: PubMed
  81. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002; 42:165-79.
    View in: PubMed
  82. Frazier JA, Doyle R, Chiu S, Coyle JT. Treating a child with Asperger's disorder and comorbid bipolar disorder. Am J Psychiatry. 2002 Jan; 159(1):13-21.
    View in: PubMed
  83. Leski ML, Hassinger LC, Valentine SL, Baer JD, Coyle JT. L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure. Synapse. 2002 Jan; 43(1):30-41.
    View in: PubMed
  84. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1367-77.
    View in: PubMed
  85. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1; 49(3):289-99.
    View in: PubMed
  86. Leski ML, Valentine SL, Baer JD, Coyle JT. Insulin-like growth factor I prevents the development of sensitivity to kainate neurotoxicity in cerebellar granule cells. J Neurochem. 2000 Oct; 75(4):1548-56.
    View in: PubMed
  87. Leveque JC, Macías W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li XM, Coyle JT, Huganir RL, Heckers S, Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 2000 Jun 1; 20(11):4011-20.
    View in: PubMed
  88. Nguyen TV, Brownell AL, Iris Chen YC, Livni E, Coyle JT, Rosen BR, Cavagna F, Jenkins BG. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse. 2000 Apr; 36(1):57-65.
    View in: PubMed
  89. Price BH, Adams RD, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology. 2000 Jan 11; 54(1):8-14.
    View in: PubMed
  90. Coyle JT, Schwarcz R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000 Jan; 57(1):90-3.
    View in: PubMed
  91. Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C, Coyle JT. Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol. 1999 Dec 6; 415(1):52-64.
    View in: PubMed
  92. Lindley CR, Coyle JT. Psychopharmacologist as family doctor: complications in the joint treatment of a husband and wife. Harv Rev Psychiatry. 1999 Nov-Dec; 7(4):222-9.
    View in: PubMed
  93. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov; 156(11):1822-5.
    View in: PubMed
  94. Leski ML, Valentine SL, Coyle JT. L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. Brain Res. 1999 May 15; 828(1-2):27-40.
    View in: PubMed
  95. Coyle JT. Ice-nine and human prion disease. Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):331-3.
    View in: PubMed
  96. Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999 Mar; 156(3):467-9.
    View in: PubMed
  97. Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi AR, Coyle JT. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol. 1999 Jan; 55(1):179-85.
    View in: PubMed
  98. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999 Jan; 56(1):21-7.
    View in: PubMed
  99. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15730-4.
    View in: PubMed
  100. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1; 44(11):1081-9.
    View in: PubMed
  101. Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry. 1998 Oct 15; 44(8):667-74.
    View in: PubMed
  102. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998 Sep; 155(9):1207-13.
    View in: PubMed
  103. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998 Aug; 286(2):1020-5.
    View in: PubMed
  104. Schwartz PJ, Coyle JT. Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse. 1998 Jul; 29(3):206-12.
    View in: PubMed
  105. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res. 1998 Jun 8; 795(1-2):341-8.
    View in: PubMed
  106. Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry. 1998 Jun; 155(6):726-32.
    View in: PubMed
  107. Steingard RJ, Schmidt C, Coyle JT. Basic neuroscience: critical issues for understanding psychiatric disorders. Adolesc Med. 1998 Jun; 9(2):205-15, v.
    View in: PubMed
  108. Passani L, Elkabes S, Coyle JT. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Res. 1998 May 25; 794(1):143-5.
    View in: PubMed
  109. Schwartz PJ, Reaume A, Scott R, Coyle JT. Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Res. 1998 Apr 6; 789(1):32-9.
    View in: PubMed
  110. Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3215-20.
    View in: PubMed
  111. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998; 49:173-84.
    View in: PubMed
  112. Orlando LR, Luthi-Carter R, Standaert DG, Coyle JT, Penney JB, Young AB. N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci Lett. 1997 Oct 31; 236(2):91-4.
    View in: PubMed
  113. Passani LA, Vonsattel JP, Coyle JT. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 1997 Oct 24; 772(1-2):9-22.
    View in: PubMed
  114. Coyle JT, Mallet J. Disease, transplantation and regeneration. Curr Opin Neurobiol. 1997 Oct; 7(5):663-5.
    View in: PubMed
  115. Passani LA, Vonsattel JP, Carter RE, Coyle JT. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol. 1997 Jun; 31(2):97-118.
    View in: PubMed
  116. Coyle JT. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis. 1997; 4(3-4):231-8.
    View in: PubMed
  117. Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT. Kainic acid induces apoptosis in neurons. Neuroscience. 1996 Dec; 75(4):1047-55.
    View in: PubMed
  118. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996 Dec; 153(12):1628-30.
    View in: PubMed
  119. Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT. Kainate induces apoptosis in neurons. Neuroscience. 1996 Oct; 74(3):675-83.
    View in: PubMed
  120. Didier M, Bursztajn S, Adamec E, Passani L, Nixon RA, Coyle JT, Wei JY, Berman SA. DNA strand breaks induced by sustained glutamate excitotoxicity in primary neuronal cultures. J Neurosci. 1996 Apr 1; 16(7):2238-50.
    View in: PubMed
  121. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A. 1996 Jan 23; 93(2):749-53.
    View in: PubMed
  122. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 1996; 36:83-106.
    View in: PubMed
  123. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996 Jan-Feb; 3(5):241-53.
    View in: PubMed
  124. Coyle JT. Food for thought. Nat Med. 1995 Oct; 1(10):1006-7.
    View in: PubMed
  125. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995 Oct; 52(10):829-36.
    View in: PubMed
  126. Baer L, Cukor P, Jenike MA, Leahy L, O'Laughlen J, Coyle JT. Pilot studies of telemedicine for patients with obsessive-compulsive disorder. Am J Psychiatry. 1995 Sep; 152(9):1383-5.
    View in: PubMed
  127. Schwartz PJ, Berger UV, Coyle JT. Mice transgenic for copper/zinc superoxide dismutase exhibit increased markers of biogenic amine function. J Neurochem. 1995 Aug; 65(2):660-9.
    View in: PubMed
  128. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 1995 Aug; 46(5):531-40.
    View in: PubMed
  129. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995 Aug; 152(8):1213-5.
    View in: PubMed
  130. Baer L, Jacobs DG, Cukor P, O'Laughlen J, Coyle JT, Magruder KM. Automated telephone screening survey for depression. JAMA. 1995 Jun 28; 273(24):1943-4.
    View in: PubMed
  131. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995 Mar; 152(3):332-40.
    View in: PubMed
  132. Berger UV, Carter RE, McKee M, Coyle JT. N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. J Neurocytol. 1995 Feb; 24(2):99-109.
    View in: PubMed
  133. Berger UV, Carter RE, Coyle JT. The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience. 1995 Feb; 64(4):847-50.
    View in: PubMed
  134. Tsai G, Cork LC, Slusher BS, Price D, Coyle JT. Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. Brain Res. 1993 Dec 3; 629(2):305-9.
    View in: PubMed
  135. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993 Oct 29; 262(5134):689-95.
    View in: PubMed
  136. Puttfarcken PS, Getz RL, Coyle JT. Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells. Brain Res. 1993 Oct 8; 624(1-2):223-32.
    View in: PubMed
  137. Tsai G, Slusher BS, Sim L, Coyle JT. Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. J Chem Neuroanat. 1993 Sep-Oct; 6(5):277-92.
    View in: PubMed
  138. Puttfarcken PS, Handen JS, Montgomery DT, Coyle JT, Werling LL. N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther. 1993 Aug; 266(2):796-803.
    View in: PubMed
  139. Puttfarcken PS, Lyons WE, Coyle JT. Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. Neuropharmacology. 1992 Jun; 31(6):565-75.
    View in: PubMed
  140. Coyle JT. Basic models of Alzheimer's disease. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A:35A.
    View in: PubMed
  141. Schwarcz R, Bennett JP, Coyle JT. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease. J Neurochem. 1977 Apr; 28(4):867-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Coyle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_